Elevar Therapeutics Announces FDA PDUFA Date for Resubmitted New Drug Application for Rivoceranib in Combination With Camrelizumab for Use as a First-line Systemic Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

FORT LEE, N.J., Nov. 05, 2026 -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients with cancer, today announced the U.S. Food and Drug Administration (FDA) acknowledged receipt of the resubmission of a new drug application (NDA) for its investigational drug rivoceranib, an oral VEGF-TKI, in combination with camrelizumab, an anti-PD-1 antibody, as a first-line systemic treatment for unresectable or metastatic hepatocellular carcinoma (uHCC). The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 9, 2027. HCC is the most common type of liver cancer.